STAT’s Post

Kura Oncology, Inc. has signed a global partnership with Japanese drugmaker Kyowa Kirin, Inc.- U.S. to develop and sell an experimental #leukemia treatment. The Kura-Kyowa tie-up was announced just days after competitor Syndax Pharmaceuticals won U.S. approval for a similar drug. Kyowa is paying $330 million to Kura in exchange for licensing rights to the drug, called ziftomenib. https://trib.al/e6FAoFa